Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 9/20 | 0.52 |
| ▸ | CTSL | P07711 | 6/20 | 0.52 |
| ▸ | CTSS | P25774 | 4/20 | 0.52 |
| ▸ | CTSB | P07858 | 2/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.51 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3334002 | 1.00 | TSHR (0.53) | TSHRALDH1A1CYP1A2POLBCYP2C9 | |
| SCHEMBL3331640 | 0.91 | P2RY12 (0.51) | CTSKCTSLCTSSCTSBP2RX7 | |
| SCHEMBL3331645 | 0.91 | P2RY12 (0.51) | CTSKCTSLCTSSCTSBP2RX7 | |
| SCHEMBL953167 | 0.89 | TSHR (0.51) | TSHRALDH1A1CYP1A2POLBCYP2C9 | |
| SCHEMBL953169 | 0.89 | TSHR (0.51) | TSHRALDH1A1CYP1A2POLBCYP2C9 | |
| SCHEMBL953165 | 0.89 | TSHR (0.51) | TSHRALDH1A1CYP1A2POLBCYP2C9 | |
| SCHEMBL2583553 | 0.87 | P2RY12 (0.58) | TSHRALDH1A1CYP1A2POLBCYP2C9 | |
| SCHEMBL2583559 | 0.87 | P2RY12 (0.58) | TSHRALDH1A1CYP1A2POLBCYP2C9 | |
| SCHEMBL954457 | 0.86 | TGM2 (0.55) | TSHRALDH1A1CYP1A2POLBCYP2C9 | |
| SCHEMBL954454 | 0.86 | TGM2 (0.55) | TSHRALDH1A1CYP1A2POLBCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8669266-B2 | Quinoline-carboxamide derivatives as P2Y12 antagonists | SANOFI (FR) | 2014-03-11 | — | — | US | disclosed |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2148871-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008128647-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | P2RY12, P2RY1, P2RY2 | TSHR 916/4885ALDH1A1 2297/4885CYP1A2 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.